Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

doi:10.1158/1078-0432.CCR-17-2781

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2018

Pietrantonio Filippo, Fucà Giovanni, Morano Federica, Gloghini Annunziata, Corso Simona, Aprile Giuseppe, Perrone Federica, De Vita Ferdinando, Tamborini Elena, Tomasello Gianluca, Gualeni Ambra Vittoria, Ongaro Elena, Busico Adele, Giommoni Elisa, Volpi Chiara Costanza, Laterza Maria Maddalena, Corallo Salvatore, Prisciandaro Michele, Antista Maria, Pellegrinelli Alessandro, Castagnoli Lorenzo, Pupa Serenella M, Pruneri Giancarlo, de Braud Filippo, Giordano Silvia, Cremolini Chiara, Di Bartolomeo Maria

Abstract excerpt

Purpose: Refining the selection of HER2-positive metastatic gastric cancer patient candidates for trastuzumab is a challenge of precision oncology. Preclinical studies have suggested several genomic mechanisms of primary resistance, leading to activation of tyrosine kinase receptors other than HER2 or downstream signaling pathways.Experimental Design: We carried out this multicenter, prospective, case-control...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Patient Selection

Share to Precision Medicine

Share to Progression-Free Survival

Share to Receptor, ErbB-2

Share to Stomach Neoplasms

Share to Survival Analysis

Share to Trastuzumab

Source

Open in PubMed

Identifiers

PMID: 29208673
DOI: 10.1158/1078-0432.CCR-17-2781

Genes

EGFR
KRAS
MET
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.PMID 29208673Read ↗

High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report.Semantic proximity Read ↗

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with TrastuzumabSemantic proximity Read ↗

Prospective comprehensive genomic profiling of advanced gastric carcinoma cases reveals frequent clinically relevant genomic alterations and new routes for targeted therapies.Semantic proximity Read ↗

Exploring potential molecular resistance and clonal evolution in advanced HER2-positive gastric cancer under trastuzumab therapySemantic proximity Read ↗

The genomics and therapeutics of HER2-positive gastric cancer—from trastuzumab and beyondSemantic proximity Read ↗

Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer.Semantic proximity Read ↗

Towards the goal of personalized medicine in gastric cancer--time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway.Semantic proximity Read ↗

Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancerSemantic proximity Read ↗

First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-positive gastric cancer with sequential genomic profilingSemantic proximity Read ↗

Genomic correlations for clinical outcomes in HER2-positive advanced gastric cancers treated using trastuzumab-based therapySemantic proximity Read ↗

Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.Semantic proximity Read ↗

Clinical implications of plasma ctDNA features and dynamics in gastric cancer treated with HER2‐targeted therapiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.